Quinolone Resistance – Causes, Risks and Treatment

What is Quinolone Resistance?

Quinolone resistance describes the capacity of certain bacteria to survive and multiply despite exposure to quinolone antibiotics (including fluoroquinolones). Quinolones are a widely used class of broad-spectrum antibiotics prescribed for urinary tract infections, respiratory infections, gastrointestinal infections, and more. When bacteria develop resistance to these drugs, treatment becomes significantly more challenging and can lead to therapeutic failure.

Mechanism of Action of Quinolones

Quinolones work by inhibiting two essential bacterial enzymes: DNA gyrase and topoisomerase IV. These enzymes are critical for the unwinding, replication, and repair of bacterial DNA. By blocking these targets, quinolones disrupt bacterial DNA replication, ultimately causing bacterial cell death. This mechanism of action makes quinolones effective against a wide range of gram-negative and gram-positive pathogens.

Causes and Mechanisms of Resistance

Quinolone resistance can arise through several distinct molecular mechanisms:

• Chromosomal mutations: Point mutations in the genes encoding DNA gyrase (gyrA, gyrB) and topoisomerase IV (parC, parE) alter the target binding sites, reducing the affinity of quinolones for these enzymes.
• Altered membrane permeability: Bacteria may reduce the expression of outer membrane proteins (porins), limiting the entry of quinolones into the cell, or may overexpress efflux pumps that actively transport the antibiotic out of the cell.
• Plasmid-mediated quinolone resistance (PMQR): Resistance genes such as qnr genes can be transferred between bacteria via plasmids. These genes encode proteins that protect the target enzymes from quinolone binding. Enzymes like AAC(6')-Ib-cr, which chemically modify quinolones, are also plasmid-encoded.
• Biofilm formation: Bacteria embedded in biofilms are less accessible to antibiotics and often display increased tolerance to quinolones.

Risk Factors and Global Spread

Quinolone resistance has increased dramatically worldwide over recent decades. Key risk factors include:

• Frequent or inappropriate use of quinolones in human medicine and veterinary practice
• Self-medication without medical supervision
• Incomplete antibiotic treatment courses
• Spread of resistant strains in healthcare settings (nosocomial infections) and the community
• International travel to regions with high resistance prevalence

Pathogens most commonly associated with quinolone resistance include Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Salmonella species.

Clinical Significance

Infections caused by quinolone-resistant bacteria are associated with more severe disease courses, prolonged hospital stays, and increased mortality. Since quinolones serve as important reserve antibiotics for specific infections, their loss of efficacy forces clinicians to rely on alternative agents that may be more toxic, more expensive, or less effective. In cases involving multidrug-resistant organisms, treatment options can become critically limited.

Diagnosis

Quinolone resistance is identified in the laboratory through antimicrobial susceptibility testing (antibiogram). Bacterial samples from patient specimens -- such as urine, blood, or wound swabs -- are cultured and tested against a panel of antibiotics including quinolones. Modern PCR-based molecular methods can also directly detect specific resistance genes, enabling faster and more precise diagnosis.

Treatment and Therapeutic Alternatives

When quinolone resistance is confirmed, treatment must be adjusted based on the pathogen, the site of infection, and the resistance profile:

• Beta-lactam antibiotics (e.g., cephalosporins, carbapenems) for gram-negative pathogens
• Aminoglycosides in combination regimens
• Fosfomycin for urinary tract infections
• Nitrofurantoin for uncomplicated lower urinary tract infections
• In severe multidrug-resistant cases: polymyxins (e.g., colistin) as a last-resort option

Prevention and Resistance Management

Containing the spread of quinolone resistance requires a comprehensive approach:

• Rational prescribing guided by antibiotic stewardship principles
• Strict adherence to infection control and hygiene measures in healthcare facilities
• Avoiding unnecessary quinolone prescriptions
• Surveillance and monitoring of resistance trends through programs such as EARS-Net (European Antimicrobial Resistance Surveillance Network)
• Public education on responsible antibiotic use

References

1. World Health Organization (WHO). Global action plan on antimicrobial resistance. Geneva: WHO Press, 2015. Available at: https://www.who.int/publications/i/item/9789241509763
2. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354:12-31. doi:10.1111/nyas.12830
3. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance in the EU/EEA (EARS-Net) - Annual Epidemiological Report 2023. Stockholm: ECDC; 2023.